Company Overview and News

1
Is PDL BioPharma (PDLI) a Great Stock for Value Investors?

2018-09-21 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
UTX PDLI EOG

1
Why Is PDL BioPharma (PDLI) Up 2.5% Since Last Earnings Report?

2018-09-07 zacks
It has been about a month since the last earnings report for PDL BioPharma (PDLI - Free Report) . Shares have added about 2.5% in that time frame, outperforming the S&P 500.
ALLY TGI KORS PDLI

4
1
Assertio Therapeutics and Purdue Pharma Settle Patent Infringement Lawsuit

2018-08-28 globenewswire
LAKE FOREST, Ill., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that the Company has entered into a settlement agreement with Purdue Pharma L.P. with regard to the Company’s patent infringement lawsuit against Purdue in the U.S. District Court for the District of New Jersey, in which the Company alleged infringement by Purdue of certain of the Company’s patents in relation to Purdue’s commercialization of Oxycontin® (oxycodone hydrochloride-controlled release).
ASRT PDLI

1
PDLI / PDL BioPharma, Inc. 10-Q (Quarterly Report)

2018-08-09 sec.gov
Document UNITED STATES
PDLI

6
PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y

2018-08-09 zacks - 3
PDL BioPharma, Inc. (PDLI - Free Report) delivered earnings of 10 cents per share in the second quarter of 2018, beating the Zacks Consensus Estimate of 6 cents. However, the company’s bottom line was higher at 26 cents in the year-ago period.
GD GILD BIIB ZTO ILMN PDLI

3
PDL BioPharma Inc. (PDLI) CEO John McLaughlin on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha - 2
Welcome to the PDL BioPharma's Second Quarter 2018 Financial Results Conference Call. At this time all participants are in a listen-only mode. Following the management’s prepared remarks, we will hold a Q&A session [Operator Instructions] As a reminder, this is being recorded as of Wednesday August 8, 2018.
PDLI

7
Depomed's (DEPO) CEO Arthur Higgins on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha - 2
Good morning, and welcome to the Depomed, Inc. Second Quarter 2018 Financial Results Call. My name is Louis, and I will be facilitating the audio portion of today’s interactive broadcast. [Operator Instructions] At this time, I would like to turn the show over to Mr. John Thomas, Senior Vice President for Investor Relations and Corporate Communications. Mr. Thomas, you may begin your conference.
IRWD COLL DEPO PDLI

4
Depomed Announces Second-Quarter 2018 Financial Results

2018-08-08 globenewswire - 2
-- Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise --
COLL DEPO PDLI

3
PDL Biopharma: Sum-Of-The-Parts Analysis Suggests Downside Protection, And Optionality On Private Equity Investments

2018-07-27 seekingalpha - 1
PDLI looks cheap based on its net cash, fair value of royalty contract and loan portfolios.
MRK CRVW PE DEPO PDLI

23
Forty Seven IPO: Google Has A Stake, But Other Competitors Trade At Lower Valuations

2018-07-06 seekingalpha - 7
Entities affiliated with Google own 5.2% stake in the company. Clients of Wellington Management Company have 6.8% stake as well.
ORPHF ABT MKGAF AMGN CELGZ GILD SURF GOOG TRIL ABT RHHBF ARTH RHHVF MKGAY MRK CELG RHHBY FTSV PDLI

6
Is PDL BioPharma (PDLI) a Great Stock for Value Investors?

2018-07-04 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
JAKK BLT BHP BHPBF BBL BHP BHPLF PDLI

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to PDLI / PDL BioPharma, Inc. on message board site Silicon Investor.

Thoughts on BioPharma, Inc. (PDLI) Thoughts on BioPharma, Inc. (PDLI) Thoughts on BioPharma, Inc. (PDLI) Protein Design Labs (PDLI): Stock strong Protein Design Labs (PDLI): Stock strong Protein Design Labs (PDLI): Stock strong
CUSIP: 69329Y104